Hemostemix Inc (TSXV:HEM)
C$ 0.07 -0.01 (-12.5%) Market Cap: 9.85 Mil Enterprise Value: 14.56 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 0/100

Hemostemix Inc at Emerging Growth Conference Transcript

Oct 26, 2022 / 04:00PM GMT
Release Date Price: C$0.125 (-16.67%)
Ana Berry
Emerging Growth Conference - Media

Welcome back, everyone. Sorry about the technical difficulties with ARMT. They will be joining us again in two weeks. But let's introduce our next presenter. We have Hemostemix. It trades on the OTCQB under the symbol HMTXF and on the TSX under the symbol HEM. Founded in 2003, Hemostemix is an autologous stem cell therapy company and a winner of the World Economic Forum Technology Pioneer Award.

The company developed and has published seven peer-reviewed articles about the safety and efficacy of its lead product, ACP-01, as a treatment of CLI, PAD, angina, ischemic cardiomyopathy, dilated cardiomyopathy, and other conditions of ischemia. Please welcome its Co-founder, President, and CEO, Thomas Smeenk. Welcome back, Thomas, how you doing?

Thomas Smeenk
Hemostemix Inc. - Co-founder, President, & CEO

I'm very well, Anna. Thank you. How are you?

Ana Berry
Emerging Growth Conference - Media

Great. That was a mouthful. I hope I pronounced everything correctly.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot